Down-regulation of CD 20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies : its prevalence and clinical significance

1 Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan; 2 Department of Hematology, Toyota Memorial Hospital, Toyota, Aichi, Japan; 3 Department of Pathology, Nagoya Red-Cross First Hospital, Nagoya, Aichi, Japan; 4 Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya, Aichi, Japan; and 5 Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, Aichi, Japan

[1]  B. Cheson.  Monoclonal antibody therapy for B-cell malignancies. , 2006, Seminars in oncology.

[2]  A. Shamseddine,et al.  Loss of CD20 expression in relapsed lymphomas after rituximab therapy , 2003, European journal of haematology.

[3]  R. Bosch-Príncep,et al.  CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature , 2003, Annals of Hematology.

[4]  S. Aizawa,et al.  Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines. , 2006, Leukemia research.

[5]  N. Mitsiades,et al.  Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies , 2001, Journal of immunotherapy.

[6]  B. Bonavida,et al.  ‘Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions’ , 2007, Oncogene.

[7]  Mitchell R. Smith.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.

[8]  M. Czuczman,et al.  Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels , 2008, Clinical Cancer Research.

[9]  P. Chu,et al.  Recurrent B-cell Neoplasms After Rituximab Therapy: An Immunophenotypic and Genotypic Study , 2002, Leukemia & lymphoma.

[10]  C. Tripodo,et al.  In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. , 2007, Cancer research.

[11]  T. Kinoshita,et al.  CD20-negative relapse in B-cell lymphoma after treatment with Rituximab. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Takaoka,et al.  Comparing antibody and small-molecule therapies for cancer , 2006, Nature Reviews Cancer.

[13]  D. Czerwinski,et al.  Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  Peter A. Jones,et al.  Epigenetics in human disease and prospects for epigenetic therapy , 2004, Nature.

[15]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Czuczman,et al.  CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma , 2007, Leukemia & lymphoma.

[17]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Barbui,et al.  CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. , 2001, Blood.

[19]  H. Kantarjian,et al.  Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. , 2003, Blood.

[20]  P. Marlton,et al.  Incidence and nature of CD20‐negative relapses following rituximab therapy in aggressive B‐cell non‐Hodgkin's lymphoma: a retrospective review , 2002, British journal of haematology.

[21]  T. Naoe,et al.  Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy , 2007, International journal of hematology.

[22]  G. Nuovo,et al.  The absence of CD20 messenger RNA in recurrent cutaneous B‐cell lymphoma following rituximab therapy , 2005, Journal of cutaneous pathology.

[23]  W. Hiddemann,et al.  Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a pros , 2006, Blood.

[24]  C. Doglioni,et al.  Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma. , 2007, Haematologica.

[25]  J. Byrd,et al.  Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Randy D Gascoyne,et al.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[28]  B. Lucas,et al.  PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. , 1997, Blood.

[29]  R. Mertelsmann,et al.  The epitope recognized by rituximab. , 2006, Blood.

[30]  M Taniwaki,et al.  Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  M. Cragg,et al.  Mechanisms of killing by anti-CD20 monoclonal antibodies. , 2007, Molecular immunology.

[32]  E. McBurney,et al.  CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy. , 2002, Journal of the American Academy of Dermatology.

[33]  Max Wolf,et al.  Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. , 2006, Blood.

[34]  Lisa L. Smith,et al.  Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. , 2008, Blood.

[35]  K. Helm,et al.  Cutaneous B‐cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy , 2003, Journal of cutaneous pathology.

[36]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[37]  Yunbo Shi,et al.  Fusion Protein of Retinoic Acid Receptor α with Promyelocytic Leukemia Protein or Promyelocytic Leukemia Zinc Finger Protein Recruits N-CoR-TBLR1 Corepressor Complex to Repress Transcription in Vivo* , 2003, Journal of Biological Chemistry.

[38]  T. Ittel,et al.  Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  T. Naoe,et al.  Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo. , 2006, Biochemical and biophysical research communications.

[40]  L. Kanz,et al.  CLONAL SELECTION OF CD20‐NEGATIVE NON‐HODGKIN'S LYMPHOMA CELLS AFTER TREATMENT WITH ANTI‐CD20 ANTIBODY RITUXIMAB , 1999, British journal of haematology.

[41]  T. Naoe,et al.  Establishment of a myeloid leukemia cell line, TRL-01, with MLL-ENL fusion gene. , 2006, Cancer genetics and cytogenetics.

[42]  T. Sakurai,et al.  Blockade of bulky lymphoma‐associated CD55 expression by RNA interference overcomes resistance to complement‐dependent cytotoxicity with rituximab , 2006, Cancer science.

[43]  C. Rubini,et al.  Bone Marrow Histopathological and Molecular Changes of Small B-Cell Lymphomas after Rituximab Therapy: Comparison with Clinical Response and Patients' Outcome , 2006, International journal of immunopathology and pharmacology.